AMAM / Ambrx Biopharma: Very Strong Rally On Positive Data, But Unstable Price

Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting more_horizontal

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. I more_horizontal

The company, formerly based in the Cayman Islands, is moving to Delaware. It is expected to announce trial data next week regarding two of its lead th more_horizontal

Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year. more_horizontal

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time cl more_horizontal

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Con more_horizontal

Ambrx Biopharma's stock value has surged due to positive preliminary data from cancer-targeting clinical trials of ARX788 and ARX517. With cash reserv more_horizontal

Ambrx's lead therapies target breast cancer and prostate cancer, two of the most common forms of cancer. The company has enough cash, it said, to fund more_horizontal